

Study Title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Of A Novel CCR5 Antagonist, UK 427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone For The Treatment of Antiretroviral-Experienced HIV 1 Infected Subjects. A4001027

Category

Antiretroviral trial – Treatment Experienced

Status

Enrolment complete

Primary Investigator at TGH

Dr. Sharon Walmsley

Sponsor

Pfizer

Brief Description of the Study

A Phase II/III study comparing Pfizer CCR5 inhibitor (150mg QD or 150 mg BID) along with Optimized Background Regimen to Optimized Background Regimen alone in HIV 1 treatment experienced patients. This is a placebo controlled double-blinded study with a duration of 48 weeks.

Contact

Rosie Clarke – 416-340-4800 ext. 6723,

email – rosie.clarke@uhn.on.ca